

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB Case No. 02-742-O; 400/144)

In the Application of:)
McSwiggen et al.)
Serial No.: 10/764,957) Examiner: GIBBS, Terra C.
Filing Date: January 26, 2004) Group Art Unit: 1635
For: RNA Interference Mediated Inhibition) Confirmation No. 9923
Of Vascular Endothelial Growth Factor)
And Vascular Endothelial Growth Factor)
Receptor Gene Expression Using Short)
Interfering Nucleic Acid (siRNA))

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Sections 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Fourth Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Applicant provides copies of references that are indicated by number on the enclosed PTO-1449 form, while no copies of references indicated with *** are submitted.

Portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants enclose the fee of \$180.00 pursuant to 37 C.F.R. 1.17(p) for this filing. The Commissioner is hereby authorized to charge or credit Deposit Account Number 13-2490 for any under- or over-payment of fees associated with the papers transmitted herewith, or to credit any overpayment of same.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: May 17, 2007

By: Christopher P. Singer
Christopher P. Singer
Registration No. 48,701

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002